Immunological aspects related to re-infection by SARS-CoV-2
DOI:
https://doi.org/10.37135/ee.04.10.09Keywords:
SARS-CoV-2, COVID-19, Immune DisordersAbstract
At the end of 2019, a new strain of coronavirus (SARS-CoV-2) causes a notable global crisis. The efforts of health personnel have focused on learning about the novel disease and finding a way to slow down the contagion curves to have immunity from vaccines in the future. Immunity to primary B lymphocyte-mediated infection has reported the loss of immunoglobulins in a matter of weeks. These characteristics in the genotype of the disease open the possibility of reinfection by different strains. Counted reports worldwide describe reinfection, which had a mild clinical course when determining some protective factor after the primary infection. The real possibility of getting sick again from COVID-19 raises the alarms about the response in the control of the pandemic, with the vaccines that are close to being distributed and represent a new field of study in the current health emergency.
Downloads
References
OPS. Informes de situación de la COVID-19. [Internet]. Washington: OPS; 2020 [citado 18 nov 2020]. Disponible en: www.paho.org/es/informes-situacion-covid-19.
OPS/OMS. Alerta Epidemiológica: oleadas y brotes recurrentes de COVID-19. [Internet]. Washington: OPS; 2020 [citado 18 nov 2020]. Disponible en: https://www.paho.org/es/documentos/alerta-epidemiologica-oleadas-brotes-recurrentes-covid-19#:~:text=En%20abril%20de%202020%2C%20la,la%20Regi%C3%B3n%20de%20las%20Am%C3%A9ricas.
MSP. Infografía N°196. Situación Nacional por Covid-19. [Internet]. Quito: MSP; 2020 [citado 18 nov 2020]. Disponible en: https://www.salud.gob.ec/el-ministerio-de-salud-publica-del-ecuador-msp-informa-situacion-coronavirus/.
Gobierno de España/ Ministerio de Sanidad. Manejo en atención primaria y domiciliaria del COVID-19. Documento técnico [Internet]. Madrid: Ministerio de Sanidad; 2020 [actualizado 18 Jun 2020; citado 18 nov 2020]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Manejo_primaria.pdf
Centers for Disease Control and Prevention. Duration of Isolation and Precautions for Adults with COVID-19. [Internet]. USA: Centers for Disease Control and Prevention; 2020 [citado 18 nov 2020]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcommunity%2Fstrategy-discontinue-isolation.html.
Chen Z, John E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020; 20(9): 529-536.
Batisse D, Benech N, Botelho-Nevers E, Bouiller K, Collarino R, Conrad A, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infection [Internet]. 2020 [citado 18 Nov 2020]; (81): 816-846. Disponible en: https://www.journalofinfection.com/action/showPdf?pii=S0163-4453%2820%2930454-0.
Molina LP, Chow SK, Nickel A, Love JE. Prolonged Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an Obstetric Patient With Antibody Seroconversion. Obstet Gynecol [Internet]. 2020 [citado 1 Sep 2020]; 136(4): 838-841. Disponible en: https://journals.lww.com/greenjournal/Fulltext/2020/10000/Prolonged_Detection_of_Severe_Acute_Respiratory.30.aspx
Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: Retrospective cohort study. The BMJ [Internet]. 2020 [citado 18 Nov 2020];369:1143. Disponible en: https://www.bmj.com/content/369/bmj.m1443
Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell [Internet]. 2020 [citado 18 Nov 2020]; 181(7): 1489-1501. Disponible en: https://www.cell.com/cell/fulltext/S0092-8674(20)30610-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420306103%3Fshowall%3Dtrue.
Duggan NM, Ludy SM, Shannon BC, Reisner AT, Wilcox SR. Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results through a case report. The American Journal of Emergency Medicine [Internet]. 2020 [citado 18 Nov 2020]. Disponible en: https://www.ajemjournal.com/action/showPdf?pii=S0735-6757%2820%2930583-0
León X, Otero F. Desarrollo de vacunas contra SARS-CoV-2. Acta Pediatr Mex INP. 2020; 41(1): 23-26.
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus research [Internet]. 2020 [citado 18 Nov 2020]; 288: 1-12. Disponible en: https://reader.elsevier.com/reader/sd/pii/S0168170220310212?token=FD34FB334DF1E5ACC44642FEA0624B655BD1F6922554FA83489BE8F59C73C720FC7908C3CA934395C70A00C96241DDBF.
The Gamaleya National Center. Sputnik V. The first registered Covid-19 vaccine proven human Adenoviral Vector Technology. [Internet]. Moscow: The Gamaleya National Center; 2020 [citado 18 nov 2020]. Disponible en: https://www.gamaleya.org/about/obshchaya-informatsiya/.
Sociedad Española de Medicina de Urgencias y Emergencias. Grupo de Infecciones en Urgencias INFURG-SEMES. Serotipos SARS-CoV-2 y reinfección por COVID-19. Información y explicación de la pandemia del siglo XXI COVID [Internet]. Madrid: Sociedad Española de Medicina de Urgencias y Emergencias; 2020 [actualizado 01 May 2020; citado 18 nov 2020]. Disponible en: https://www.semes.org/wp-content/uploads/2020/05/P%C3%ADldora-6-Serotipos-SARS-CoV-2-y-reinfecci%C3%B3n-por-COVID-19.pdf
Pastrian SG. Bases genéticas y moleculares del COVID-19 (SARS-CoV-2). Mecanismos de patogénesis y de respuesta inmune. Int. J. Odontostomat. [Internet]. 2020 [citado 18 Nov 2020]; 14(3): 331-337. Disponible en: https://scielo.conicyt.cl/pdf/ijodontos/v14n3/0718-381X-ijodontos-14-03-331.pdf
Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. bioRxiv: the preprint server for biology [Internet]. 2020 [citado 18 Nov 2020]; 2020: 1-36. Disponible en: https://www.biorxiv.org/content/10.1101/2020.06.05.134551v1.full.pdf+html.
Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane [Internet]. 2020 [citado 18 Nov 2020]. Disponible en: https://www.cochrane.org/CD013705/INFECTN_how-accurate-are-rapid-tests-performed-during-health-care-visit-point-care-diagnosing-covid-19?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+NewAndUpdatedSummaries+%28New+and+updated+Cochrane+summaries%29.
Pepper M, Rodda L, Netland J, Shehata L, Pruner K, Morawski P, et al. Rawlings D. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Research Square [Internet]. 2020 [citado 18 Nov 2020]; In press: 1-56. Disponible en: https://www.researchsquare.com/article/rs-57112/v1.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Desregulación de la respuesta inmune en pacientes con coronavirus 2019 (COVID-19) en Wuhan, China. Enfermedades Infecciosas Clínicas [Internet]. 2020 [citado 18 Nov 2020]; 71(15): 762–768. Disponible en: https://academic.oup.com/cid/article/71/15/762/5803306.
Kai-Wang K, Fan-Ngai I, Ip JD, Wing-Ho A, Wan-Mui C, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Infectious Diseases Society of America [Internet]. 2020 [citado 18 Nov 2020]; XX(XX): 1–6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32840608/.
European Centre for Disease Prevention and Control. Reinfection with SARS-CoV: considerations for public health response. USA: ECDC; 2020.
Osman AA, Al Daajani MM, Alsahafi AJ. Prueba de PCR COVID-19 re-positiva: ¿podría ser una reinfección? Nuevos microbios y nuevas infecciones [Internet]. 2020 [citado 18 Nov 2020]; (37): 1–6. Disponible en: https://www.sciencedirect.com/science/article/pii/S2052297520301001?via%3Dihub.
